Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

VolitionRx Ltd. (VNRX) Invites Investors To View Presentation Delivered At MicroCapClub Invitational

|Includes: VolitionRX Ltd (VNRX)

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, this morning told investors that the company presented at the 2nd annual MicroCapClub Invitational. The company's presentation can be accessed at the following link:

"At MicroCapClub we have 147 experienced microcap investors discussing over 180 microcap companies in our members forum. We handpick several unique companies every year to showcase to the public," said Ian Cassel, founder of MicroCapClub. "We have been following VolitionRx since it went public a couple years ago and believe the company is now at an interesting inflection point. If the company's blood based cancer diagnostic platform is successfully validated through large clinical trials in 2014, it will be a game changer for the cancer arena and shareholders. Given the company's current valuation compared to its peer group, we feel VolitionRx is worth following."

"We have an exciting year coming up," says Cameron Reynolds, CEO of VolitionRx. "On the clinical side, we expect to publish initial results from our first major 4,800-individual colorectal cancer diagnostic trial, and begin the application process for European CE regulatory approval. We also expect to book significant early revenue from our epigenetic Research Use Kits, which will assist the company in funding our ongoing trials."

For more information on VolitionRx, visit

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit